{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.13","upperLimit":"99.64","value":"85.7"},{"groupId":"OG001","lowerLimit":"35.88","upperLimit":"99.58","value":"83.3"},{"groupId":"OG002","lowerLimit":"35.88","upperLimit":"99.58","value":"83.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"ORR=percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG response criteria. CR \\& sCR are defined as outlined in endpoint 5 (CRR/sCRR). VGPR=serum \\& urine M-protein (UMP) detectable by immunofixation, but not electrophoresis; ≥90% reduction in serum M-protein (SMP) + UMP level \\<100 mg/24 hrs; at baseline ≥90% reduction in sum of the maximal perpendicular diameter (SPD) compared with baseline for soft tissue plasmacytoma \\& ≥90% decrease in the difference between involved \\& uninvolved SFLC levels. PR=≥50% reduction in SMP \\& UMP reduction ≥90% or \\<200 mg/24hours; if SMP \\& UMP not measurable, ≥50% decrease in involved \\& uninvolved SFLC difference in place of M-protein criteria; if SMP, UMP \\& SFLC assay not unmeasurable, ≥50% reduction in plasma cells required in place of M-protein (baseline BM plasma cell ≥30%); at baseline, a ≥50% reduction in SPD of soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received step-up doses of forimtamig 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.3 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG000","title":"Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 0.75 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG001","title":"Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib"},{"description":"Participants received step-up doses of forimtamig, 0.03 mg on Cycle 1 Day 1, 0.15 mg on Cycle 1 Day 8, and the target dose of 1.5 mg on Cycle 1 Day 15 and on Days 1 and 15 of each subsequent cycle, administered as a SC injection. Participants also received carfilzomib, 20 mg/m\\^2 on Cycle 2 Day 1 and 56 mg/m\\^2 on Cycle 2 Days 8 and 15, and from Cycle 3 onwards on Days 1, 8, and 15, administered as an IV infusion (1 cycle = 28 days).","id":"OG002","title":"Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib"}],"paramType":"NUMBER","populationDescription":"Efficacy-evaluable population included all response evaluable participants, i.e., those who received at least one dose of one of their assigned study treatments and had at least one baseline and one on-treatment tumor assessment or those who had one tumor assessment at baseline and discontinued their treatment for any reason before their first on-treatment tumor assessment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15.2 months","title":"Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}